Cargando…

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

The emergence of vascular disrupting agents (VDAs) is a significant advance in the treatment of solid tumors. VDAs induce rapid and selective shutdown of tumor blood flow resulting in massive necrosis. However, a viable marginal tumor rim always remains after VDA treatment and is a major cause of re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Wenjie, Ni, Yicheng, Chen, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941252/ https://www.ncbi.nlm.nih.gov/pubmed/26812886 http://dx.doi.org/10.18632/oncotarget.6999

Ejemplares similares

Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation
por: Liu, Yewei, et al.
Publicado: (2020)

Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration
por: He, Jintong, et al.
Publicado: (2020)

Dynamic Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging Noninvasive Evaluation of Vascular Disrupting Treatment on Rabbit Liver Tumors
por: Shao, Haibo, et al.
Publicado: (2013)

Impact of Blood–Brain Barrier to Delivering a Vascular-Disrupting Agent: Predictive Role of Multiparametric MRI in Rodent Craniofacial Metastasis Models
por: Wang, Shuncong, et al.
Publicado: (2022)

Predicting Therapeutic Efficacy of Vascular Disrupting Agent CA4P in Rats with Liver Tumors by Hepatobiliary Contrast Agent Mn-DPDP-Enhanced MRI
por: Liu, Yewei, et al.
Publicado: (2019)

Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors †
por: Liu, Li, et al.
Publicado: (2021)

Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology
por: Yin, Ting, et al.
Publicado: (2017)

Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI
por: Chen, Feng, et al.
Publicado: (2012)

Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption
por: Hong, Sheng, et al.
Publicado: (2020)

Sequential Administrations of a Vascular-Disrupting Agent, High-Intensity Focused Ultrasound, and a Radioactively labeled Necrosis Avid Compound for Eradicating Solid Malignancies
por: Li, Yue, et al.
Publicado: (2022)

Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents
por: Horsman, Michael R., et al.
Publicado: (2020)

Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P
por: Liu, Yewei, et al.
Publicado: (2017)

Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors
por: Griffin, Robert J., et al.
Publicado: (2012)

Vascular disrupting agents in clinical development
por: Hinnen, P, et al.
Publicado: (2007)

Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models
por: Shao, Haibo, et al.
Publicado: (2015)

Alternative Vascularization Mechanisms in Tumor Resistance to Therapy
por: Belotti, Dorina, et al.
Publicado: (2021)

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors
por: Bähr, Oliver, et al.
Publicado: (2017)

Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption
por: Virani, Needa A., et al.
Publicado: (2020)

Comparison of Optical and Power Doppler Ultrasound Imaging for Non-Invasive Evaluation of Arsenic Trioxide as a Vascular Disrupting Agent in Tumors
por: Alhasan, Mustafa K., et al.
Publicado: (2012)

Treatment Effect of a Vascular-Disrupting Agent Dynamically Monitored by DWI: An Animal Experimental Study
por: Huang, Danping, et al.
Publicado: (2021)

Disruption of Vascular Barriers in Tumors and in the Brain
por: McDannold, Nathan
Publicado: (2015)

Evaluation of a (99m)Tc-tricine Vascular Disrupting Agent as an In-vivo Imaging in 4T1 Mouse Breast Tumor Model
por: Erfani, Mostafa, et al.
Publicado: (2017)

Vascular Disrupting Agent Drug Classes Differ in Effects on the Cytoskeleton
por: Kim, Sujeong, et al.
Publicado: (2012)

Flavonoid-Inspired Vascular Disrupting Agents: Exploring Flavone-8-Acetic Acid and Derivatives in the New Century
por: Gobbi, Silvia, et al.
Publicado: (2021)

Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents
por: Zhang, Dongjian, et al.
Publicado: (2018)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2016)

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
por: Fifis, Theodora, et al.
Publicado: (2013)

Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments
por: Nguyen, Linh, et al.
Publicado: (2012)

Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers
por: Liu, Ye-Wei, et al.
Publicado: (2018)

Clinical Application of Tumor Vascular Disrupting Therapy: A Systematic Review and Meta-Analysis
por: Tsang, Wen, et al.
Publicado: (2021)

Necrosis Avidity: A Newly Discovered Feature of Hypericin and its Preclinical Applications in Necrosis Imaging
por: Jiang, Binghu, et al.
Publicado: (2013)

Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
por: Kim, Hark Kyun, et al.
Publicado: (2020)

Tumor vascular disruption using various radiation types
por: Bevelacqua, JJ
Publicado: (2014)

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022)

Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters
por: Ahn, Su Yeon, et al.
Publicado: (2018)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer
por: Bothwell, Katelyn D., et al.
Publicado: (2016)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_pppitpme4pmcqsh1jpg3u2h8ib